Kosan Biosciences, Inc. (stock symbol: KOSN), was a pharmaceutical company which dealt with cancer therapeutics medications. The company was working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Founded in 1995, Kosan was headquartered in Hayward, California and had approximately 90 employees. Kosan was funded in part as a venture capital start-up with funds from Sofinnova Ventures of California. On June 26, 2008, Kosan Biosciences was acquired by Bristol-Myers Squibb for $190M.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - Kosan Biosciences, Inc. (stock symbol: KOSN), was a pharmaceutical company which dealt with cancer therapeutics medications. The company was working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Founded in 1995, Kosan was headquartered in Hayward, California and had approximately 90 employees. Kosan was funded in part as a venture capital start-up with funds from Sofinnova Ventures of California. On June 26, 2008, Kosan Biosciences was acquired by Bristol-Myers Squibb for $190M. (en)
|
foaf:name
| - Kosan Biosciences, Inc. (en)
|
name
| - Kosan Biosciences, Inc. (en)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
bot
| |
date
| |
fix-attempted
| |
founded
| |
hq location
| |
key people
| |
num employees
| |
has abstract
| - Kosan Biosciences, Inc. (stock symbol: KOSN), was a pharmaceutical company which dealt with cancer therapeutics medications. The company was working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Their technology platform was based on manipulation of the genetic instructions of microbes for making natural product polyketides. Rearranging the modular units in natural polyketide synthases, combining modules from different enzymes, and incorporating novel synthetic chemical starter units enabled them to produce a wide variety of novel polyketides that would be difficult to obtain via organic synthesis alone. Founded in 1995, Kosan was headquartered in Hayward, California and had approximately 90 employees. Kosan was funded in part as a venture capital start-up with funds from Sofinnova Ventures of California. On June 26, 2008, Kosan Biosciences was acquired by Bristol-Myers Squibb for $190M. (en)
|
skos:closeMatch
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
founding year
| |
number of employees
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage disambiguates
of | |
is foaf:primaryTopic
of | |